Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients

Background:Pancreatic neuroendocrine tumors (PNET) have a poorly defined natural history, and a staging system is not available. The objective of this study was to identify factors predicting survival after pancreatectomy for PNETs and to establish a postresection prognostic score. Patients and Methods:From the National Cancer Data Base (1985–2004), patients were identified who underwent PNET resection. Multivariable Cox proportional hazards modeling was used to assess the impact of patient, tumor, treatment, and hospital factors on survival. A prognostic score based on the predictive factors from the Cox model was developed. Results:Three thousand eight hundred fifty-one patients underwent resection for PNETs. Five-year overall survival was 59.3%, and the 10-year survival was 37.7%. On multivariable analysis, age, grade, distant metastases, tumor functionality, and type of resection were independent predictors of survival after resection of PNETs (P < 0.0001). Gender, race, socioeconomic status, tumor size, nodal status, margins, adjuvant chemotherapy, and hospital volume were not associated with survival. Age, grade, and distant metastases were the most significant predictors of survival and were incorporated into a PNET postresection prognostic score. The prognostic score correlated with outcomes and offered excellent survival discrimination by each of the 3 score subgroups: 76.7%, 50.9%, and 35.7% (P < 0.0001). The concordance index was 0.63 (95% CI 0.59–0.67), indicating reasonable agreement between actual outcomes and that predicted by the prognostic score. Conclusions:The prognostic score can be used to predict outcomes, guide adjuvant treatment, and stratify patients for clinical trials.

[1]  M. McCarter,et al.  Post-discharge venous thromboembolism in surgical oncology: Extending the case for extended prophylaxis , 2010 .

[2]  K. Bilimoria,et al.  A common question revisited: can differences in clinical severity explain the volume-outcome relationship? , 2010, Surgery.

[3]  M. Talamonti,et al.  Quality improvement for pancreatic cancer care: is regionalization a feasible and effective mechanism? , 2010, Surgical oncology clinics of North America.

[4]  C. Ko,et al.  The next generation of quality assessment: Developing a specialty- and outcome-specific American College of Surgeons National Surgical Quality Improvement Program , 2009 .

[5]  C. Ko,et al.  Using the NCDB for cancer care improvement: An introduction to available quality assessment tools , 2009, Journal of surgical oncology.

[6]  C. Ko,et al.  The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States , 2008, Annals of Surgical Oncology.

[7]  C. Ko,et al.  Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. , 2007, Journal of the American College of Surgeons.

[8]  C. Ko,et al.  Multimodality therapy for pancreatic cancer in the U.S. , 2007, Cancer.

[9]  C. Ko,et al.  Clinicopathologic Features and Treatment Trends of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients , 2007, Journal of Gastrointestinal Surgery.

[10]  R. Bell,et al.  Identifying patterns of adverse events: A novel system to improve surgical patient safety , 2007 .

[11]  C. Ko,et al.  Validation of the 6th edition AJCC pancreatic cancer staging system , 2007, Cancer.

[12]  V. Deshpande,et al.  Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. , 2007, Archives of surgery.

[13]  J. Izbicki,et al.  Aggressive Surgery Improves Long-term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience , 2007, Annals of surgery.

[14]  S. Choi,et al.  Malignant Nonfunctioning Endocrine Tumors of the Pancreas: Predictive Factors for Survival after Surgical Treatment , 2007, World Journal of Surgery.

[15]  M. Rothmund,et al.  An Aggressive Surgical Approach Leads to Long-term Survival in Patients With Pancreatic Endocrine Tumors , 2006, Annals of surgery.

[16]  Herb Chen,et al.  Metastatic neuroendocrine hepatic tumors: resection improves survival. , 2006, Archives of surgery.

[17]  H. Reber,et al.  Resection of pancreatic neuroendocrine tumors: results of 70 cases. , 2006, Archives of surgery.

[18]  J. Choi,et al.  Experiences with Nonfunctioning Neuroendocrine Neoplasms of the Pancreas , 2006, Digestive Surgery.

[19]  J. Norton.  Surgery for primary pancreatic neuroendocrine tumors , 2006, Journal of Gastrointestinal Surgery.

[20]  M. Falconi,et al.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. , 2005, Endocrine-related cancer.

[21]  D. Santini,et al.  Endocrine pancreatic tumors: factors correlated with survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Kattan,et al.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Ahrar,et al.  Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors , 2005, Cancer.

[24]  M. Gonen,et al.  Long-Term Survival Is Superior After Resection for Cancer in High-Volume Centers , 2005, Annals of surgery.

[25]  D. Bentrem,et al.  Outcomes in Oncologic Surgery: Does Volume Make a Difference? , 2005, World Journal of Surgery.

[26]  J. Buckels,et al.  Neuroendocrine Tumours of the Pancreas: Predictors of Survival after Surgical Treatment , 2005, Digestive Surgery.

[27]  Anneclaire J De Roos,et al.  Differences in Survival by Histologic Type of Pancreatic Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[28]  G. Doherty,et al.  The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. , 2004, Surgery.

[29]  B. Boehm,et al.  Surgery of Resectable Nonfunctioning Neuroendocrine Pancreatic Tumors , 2004, World Journal of Surgery.

[30]  R. Guo,et al.  Surgical treatment of nonfunctioning islet cell tumor: report of 41 cases. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[31]  G. Klöppel,et al.  The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification , 2004, Annals of the New York Academy of Sciences.

[32]  A. Stewart,et al.  The National Cancer Data Base: A clinical surveillance and quality improvement tool , 2004 .

[33]  L. Gullo,et al.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study , 2003, American Journal of Gastroenterology.

[34]  Peter J Pronovost,et al.  Variation in postoperative complication rates after high-risk surgery in the United States. , 2003, Surgery.

[35]  D. Nagorney,et al.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. , 2003, Journal of the American College of Surgeons.

[36]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[37]  Judy L. Smith,et al.  Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas , 2002, Annals of Surgical Oncology.

[38]  Ethan A Halm,et al.  Is Volume Related to Outcome in Health Care? A Systematic Review and Methodologic Critique of the Literature , 2002, Annals of Internal Medicine.

[39]  J. Birkmeyer,et al.  Hospital volume and surgical mortality in the United States. , 2002, The New England journal of medicine.

[40]  D. Klimstra,et al.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Jeffrey E. Lee,et al.  Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. , 2001, Surgery.

[42]  P. Gauger,et al.  Endocrine tumours of the pancreas: Review and recent advances , 2001, ANZ journal of surgery.

[43]  B. Heniford,et al.  Surgical Experience with Nonfunctioning Neuroendocrine Tumors of the Pancreas , 2000, The American surgeon.

[44]  H. Pitt,et al.  Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients , 1998, Journal of Gastrointestinal Surgery.

[45]  V. Vilgrain,et al.  Prognostic factors in patients with endocrine tumours of the duodenopancreatic area , 1998, Gut.

[46]  J. Cameron,et al.  Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients. , 1997, Surgery.

[47]  F. Sessa,et al.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours , 1996, Virchows Archiv.

[48]  J. Söreide,et al.  Islet Cell Carcinoma of the Pancreas , 1996, World Journal of Surgery.

[49]  J. Wyatt,et al.  Commentary: Prognostic models: clinically useful or quickly forgotten? , 1995 .

[50]  J. Cameron,et al.  Surgical experience with pancreatic islet-cell tumors. , 1993, Archives of Surgery.

[51]  J. Ajani,et al.  Islet cell carcinoma of the pancreas. A study of 98 patients , 1990, Cancer.

[52]  G. Thompson,et al.  Islet cell carcinomas of the pancreas: a twenty-year experience. , 1988, Surgery.

[53]  Hermann Re,et al.  Pancreatic islet cell tumors. , 1986 .

[54]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[55]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[56]  M. Talamonti,et al.  Gastric and Small Bowel Cancers , 2010 .

[57]  M. Choti,et al.  Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer , 2007, Journal of Gastrointestinal Surgery.

[58]  G. Guyatt,et al.  Clinical Prediction Rules , 2004 .

[59]  Heinz Höfler,et al.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut , 2004, Virchows Archiv.

[60]  M. Farnell,et al.  Pancreaticoduodenectomy for Islet Cell Tumors of the Head of the Pancreas: Long-term Survival Analysis , 2002, World Journal of Surgery.

[61]  B. Skogseid,et al.  Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. , 1989, Acta oncologica.

[62]  M. R. Shetty.  Pancreatic islet cell tumors. , 1987, Surgery.

[63]  R. Turell.  Society for Surgery of the Alimentary Tract , 1966 .